Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial

Autor: James F, Howard, Richard J, Nowak, Gil I, Wolfe, Miriam L, Freimer, Tuan H, Vu, John L, Hinton, Michael, Benatar, Petra W, Duda, James E, MacDougall, Ramin, Farzaneh-Far, Henry J, Kaminski, Richard, Barohn, Mazen, Dimachkie, Mamatha, Pasnoor, Constantine, Farmakidis, Tina, Liu, Samantha, Colgan, Michael G, Benatar, Tulio, Bertorini, Rekha, Pillai, Robert, Henegar, Mark, Bromberg, Summer, Gibson, Teresa, Janecki, Miriam, Freimer, Bakri, Elsheikh, Paige, Matisak, Angela, Genge, Amanda, Guidon, William, David, Ali A, Habib, Veena, Mathew, Tahseen, Mozaffar, William, Hewitt, Deborah, Barnett, Patricia, Sullivan, Doreen, Ho, Rebecca E, Traub, Manisha, Chopra, Radwa, Aly, Elham, Bayat, Mohammad, Abu-Rub, Shaida, Khan, Dale, Lange, Shara, Holzberg, Bhupendra, Khatri, Emily, Lindman, Tayo, Olapo, Lisa M, Sershon, Robert P, Lisak, Evanthia, Bernitsas, Kelly, Jia, Rabia, Malik, Tiffany D, Lewis-Collins, Michael, Nicolle, Aditi, Sharma, Bhaskar, Roy, Joan, Nye, Michael, Pulley, Alan, Berger, Yasmeen, Shabbir, Amit, Sachdev, Kimberly, Patterson, Zaeem, Siddiqi, Mark, Sivak, Joan, Bratton, George, Small, Anem, Kohli, Mary, Fetter, Tuan, Vu, Lucy, Lam, Brittany, Harvey, Nicholas, Silvestri, Kara, Patrick, Karen, Zakalik, James, MacDougall, Angela, Pontius, Michelle, Hoarty

Publikováno v: JAMA neurology. 77(5)

Importance Many patients with generalized myasthenia gravis (gMG) have substantial clinical disability, persistent disease burden, and adverse effects attributable to chronic immunosuppression. Therefore, there is a significant need for targeted, wel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9eeb0f9a4554ca1cd6226b2f14501b70
https://pubmed.ncbi.nlm.nih.gov/32065623

The effect of dimethyl fumarate (Tecfidera™) on lymphocyte counts: A potential contributor to progressive multifocal leukoencephalopathy risk

Autor: Tayo Olapo, Mary Dukic, Lisa Sershon, Bhupendra O. Khatri, Jeffery S. Garland, Joseph R. Berger, Eileen Rehn, Jean Sesing, John Kramer

Publikováno v: Multiple Sclerosis and Related Disorders. 4:377-379

Dimethyl fumarate (Tecfidera™) is an effective therapy for relapsing forms of multiple sclerosis (MS). Our study suggests that this drug may have immunosuppressive properties evidenced by significant sustained reduction in CD8 lymphocyte counts and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20243096ccfb5d93d0fb5a4882756479
https://doi.org/10.1016/j.msard.2015.05.003